regulatory requirements Archives | Quorum Review IRB

Tag Archive: regulatory requirements

  1. Phase I Healthy Study Design and IRB Review

    Comments Off on Phase I Healthy Study Design and IRB Review

    Webinar Recording: Phase I Healthy Study Design and IRB Review

    Optimize Your Phase I Healthy Trial DesignView the slides and recording for our recent webinar, Phase I Healthy Study Design and IRB Review. This webinar was originally broadcast live on October 13, 2015 and October 15, 2015.

    Presented by David C. Babaian, JD, LLM, the webinar covered:

    • Typical Phase I Healthy trial designs
    • Risks and benefits to participants in Phase I Healthy trials
    • Advertising/recruitment, informed consent, and compensation/reimbursement considerations in Phase I Healthy trials
    • Methods to minimize risks to participants in Phase I Healthy trials
    • Trends and case studies

    Webinar Slides:

    Download a PDF of the slides

    Webinar Recording:

    View the recording on YouTube below

    To access other Quorum Review webinar recordings, visit our Resources page.

     

  2. Learning from 2013 Warning Letters to IRBs

    Comments Off on Learning from 2013 Warning Letters to IRBs

    Institutional Bulletin vol 4,  issue 2

    In the recent edition of our sister publication, The Quorum Forum, we discussed reflecting on the past year as a means to formulate possible improvements to IRB procedures.  A review of FDA warning letters to IRBs from 2013 provides an opportunity to evaluate your IRB procedures and policies and evaluate them against the regulatory requirements for IRBs. If you are interested in the specifics, FDA warning letters are posted publicly on the FDA website, here.

    The handful of warning letters issued to IRBs list several failings that may seem straightforward; however, it is worthwhile to review the issues FDA raised and evaluate your own IRB procedures and policies. This exercise can help to ensure that each of these regulatory requirements is met.

    For ease of reference covering the points noted in warning letters, Quorum Review has developed a checklist for your use:

    checklist1a

    Another important point to consider is whether the study file provides adequate documentation that the above-referenced procedural requirements are followed. Once procedures have been identified that meet the regulatory requirements, it would be prudent to self-audit study files to ensure the documentation in the files clearly records that the IRB is following procedures and fulfilling regulatory obligations. 

    In addition, to procedural failings, the FDA warning letters addressed a lack of appropriate documentation in IRB minutes. Again, it may be worthwhile to review examples of recent minutes to ensure the following information is documented in minutes appropriately.

    For your convenience, Quorum Review has developed a checklist for Board minutes:

    checklist2a